Efficient targeted gene modification in primary human hematopoietic cells using co-delivery of nuclease mRNA and AAV donors
Summary for Community

- We’ve developed an approach that allows us to take patient T cells and engineer them so that they resist dominant strains of HIV and acquire desirable characteristics to help fight HIV.

- Modification of T cells using this approach is directly translatable to a range of therapeutic applications to combat HIV or HIV-associated clinical complications.